Q1 2022 Results
Company overview
Financial performance
CRM
Immunology
Financial review
Neuroscience
2022 priorities
Innovation: Pipeline overview
Ophthalmology
Appendix
Innovation: Clinical trials
Respiratory & Allergy
Oncology: Solid Tumors
Leqvio®-siRNA (regulation of LDL-C)
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
NCT03705234 ORION-4 (CKJX839B12301)
Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH)
Phase 3
~15000
A composite of major adverse cardiovascular events, defined as:
Coronary heart disease (CHD) death;
Myocardial infarction;
Fatal or non-fatal ischaemic stroke; or
Urgent coronary revascularization procedure
Arm 1: every 6 month treatment Inclisiran sodium 300mg (given by
subcutaneous injection on the day of randomization, at 3 months and then every 6-
months) for a planned median duration of about 5 years
Arm 2: matching placebo (given by subcutaneous injection on the day of
randomization, at 3 months and then every 6-months) for a planned median
duration of about 5 years.
Patient population with mean baseline LDL-C >= 100mg/dL
Read-out Milestone(s)
2026
Publication
TBD
48 Investor Relations | Q1 2022 Results
References
Abbreviations
Hematology
Biosimilars
Global Health
1 NOVARTIS | Reimagining MedicineView entire presentation